Lv51
1400 积分 2023-07-05 加入
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2个月前
已完结
For insights into the real world, consider real-world data
3个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
3个月前
已关闭
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial
3个月前
已完结
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
3个月前
已完结
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
3个月前
已完结
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
3个月前
已完结
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
4个月前
已完结
Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study
4个月前
已完结
Time-varying pattern of recurrence risk for Chinese breast cancer patients
4个月前
已完结
皖公网安备34019202002308
